Evaluation of the M371-Test Under Real-life Conditions for Diagnosis and Follow Up of Testicular Germ Cell Tumors
Anticancer Research · 2023
DOI: 10.21873/anticanres.16316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Stefan Pycha und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal, Seminoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: The aim of the study was to establish the performance of the M371-Test on the Thermocycler Rotor-GeneQ (Qiagen) platform for diagnosis and follow-up of testicular tumors and to evaluate the test under real-life conditions in comparison to the classical markers alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (β-HCG) and lactate dehydrogenase (LDH). PATIENTS AND METHODS: Forty-four patients, of median age 29 years (range=24-84) were included in this prospective study at our institution between March 2021 and September 2022. Of the 44 patients, 23 had a suspicion of testicular cancer (TC) and 21 were under follow-up for TC. In total, 96 M371-Tests were performed and compared with AFP, β-HCG, LDH using histological diagnosis and/or computer tomography (CT) scan as the gold standard. RESULTS: In the patients with suspicion of TC, the M371-Test showed a sensitivity of 73.7%, AFP of 21%, LDH of 31.6% and β-HCG of 42.1%. In the patients under follow-up for TC, the M371-Test showed a sensitivity of 86.4%, AFP of 50%, LDH of 31.8% and β-HCG of 63.6%. In germ cell tumours (GCT)/non-seminomas, M371-Test had a sensitivity of 83.3%, AFP of 77.8%, LDH of 38.9% and β-HCG of 66.7%. In GCT/seminomas, M371-Test had a sensitivity of 85%, AFP of 5%, LDH of 30% and β-HCG of 50%. CONCLUSION: Under real life conditions performed on the real-time Thermocycler Rotor-GeneQ (Qiagen) platform, the M371-Test shows an outstanding performance and is far beyond the sensitivity of the classical markers for detecting GCTs and in the follow-up of patients after GCT, especially in seminomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Bern, Bern, Switzerland.
- Department of Urology, Provincial Hospital of Bolzano, Bolzano, Italy.
- Department of Pathology, Provincial Hospital of Bolzano, Bolzano, Italy.
- Faculty of Medicine, Latvia University, Riga, Latvia.
- Sigmund Freud Private University, Vienna, Austria.
- Department of Urology, Provincial Hospital of Bolzano, Bolzano, Italy; emanuela.trenti@sabes.it.
Zitieren
APA
Pycha, S., D'Elia, C., Mian, C., Schwienbacher, C., Hanspeter, E., Palermo, M., Pycha, A., Danuser, H., & Trenti, E. (2023). Evaluation of the M371-Test Under Real-life Conditions for Diagnosis and Follow Up of Testicular Germ Cell Tumors. Anticancer Research. https://doi.org/10.21873/anticanres.16316
Vancouver
Pycha S, D'Elia C, Mian C, Schwienbacher C, Hanspeter E, Palermo M, et al. Evaluation of the M371-Test Under Real-life Conditions for Diagnosis and Follow Up of Testicular Germ Cell Tumors. Anticancer Research. 2023. doi:10.21873/anticanres.16316
BibTeX
@article{Pycha2023,
author = {Pycha, Stefan and D'Elia, Carolina and Mian, Christine and Schwienbacher, Christine and Hanspeter, Esther and Palermo, Margherita and Pycha, Armin and Danuser, Hansjörg and Trenti, Emanuela},
title = {Evaluation of the M371-Test Under Real-life Conditions for Diagnosis and Follow Up of Testicular Germ Cell Tumors},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16316}
}
EUVIMED